✦ LIBER ✦

Enzyme studies during the production of agadagidi Part 1. Amylase activities

✍ Scribed by Sanni, A. I.

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 235 KB
Volume: 32
Category: Article
ISSN: 0027-769X
DOI: 10.1002/food.19880320222

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Enzyme studies during the production of

Enzyme studies during the production of agadagidi Part 2. Invertase activities

✍ Sanni, A. I. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

Enzyme studies during the production of agadagidi Part 2. Invertase activities' A. 1. SANNI Invertase activities were assayed during fermentation period. The plantain chips, agadagidi samples, and associated microbes demonstrated invertase activities except the bacteria species. External factors suc

The 53-kDa proteolytic product of precur

The 53-kDa proteolytic product of precursor starch-hydrolyzing enzyme ofAspergillus nigerhas Taka-amylase-like activity

✍ K. Ravi-Kumar; K. S. Venkatesh; S. Umesh-Kumar 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 199 KB

Studies on Starch-Degrading Enzymes Part

Studies on Starch-Degrading Enzymes Part XI. The Stability of Crystalline Sweet Potato Beta-Amylase in Aqueous Solution

✍ W. Banks; C. T. Greenwood 📂 Article 📅 1969 🏛 John Wiley and Sons 🌐 English ⚖ 467 KB

Production of ethylene, its precursors a

Production of ethylene, its precursors and implied enzyme activities in isolated chickpea embryonic axes during the onset of growth

✍ M. M. Delgado; A. J. Matilla 📂 Article 📅 1994 🏛 Springer Netherlands 🌐 English ⚖ 587 KB

Autolysis of Saccharomyces bayanus durin

Autolysis of Saccharomyces bayanus during the production of cava Part 1. Proteolysis in wines

✍ Gordillo, C. Miguel ;Iglesias, J. L. Mesías ;Expósito, J. Marín 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

The choice of pharmacoeconomic study des

The choice of pharmacoeconomic study design during drug development—part 1

✍ Wendy Ungar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Given the rising cost of health care, it is no longer sucient to demonstrate the safety and ecacy of a medical intervention. A medication must have exhibited economic bene®t as well. Pharmaceutical manufacturers are faced with the challenge of when and how to conduct pharmacoeconomic (PE) evaluation